Loading organizations...
Loading organizations...

20n: AI-driven synthetic biology company designing genetic constructs and novel microbes for biomanufacturing and therapeutics.
20n has raised $2.0M across 1 funding round.
Key people at 20n.
20n was founded in 2015 by Saurabh Srivastava (Founder/CEO) and Chris Anderson (Founder/CSO).
20n has raised $2.0M in total across 1 funding round.
Based in San Francisco, California, 20n develops artificial intelligence and computational biology software platforms to predict biochemical reactions and design genetic constructs for synthetic biology applications. The company provides tools for predicting DNA edits and engineering custom fermentation organisms, enabling the discovery and manufacturing of novel molecules for therapeutics, flavors, and specialty chemicals. Operating through a venture-backed model, the firm builds large datasets of biochemical data by testing inventions weekly via cloud-based laboratories and offers its Bioreachables Service for custom enzymatic designs. The biotechnology startup operates with a small team of approximately two employees and has raised up to $3.3 million in seed funding to support its computational platform. The enterprise received early-stage backing from prominent startup accelerator Y Combinator as part of its Winter 2015 batch. 20n was founded in 2014 by Saurabh Srivastava.
20n was founded in 2015 by Saurabh Srivastava (Founder/CEO) and Chris Anderson (Founder/CSO).
20n has raised $2.0M in total across 1 funding round.
20n's investors include Altair Capital Management, Amino Capital, Flashpoint VC, Flex Capital, Great Oaks Venture Capital, Greylock, iNovia Capital, Journey Ventures, Locus Ventures, Matrix Capital, The Perkins Fund, TLV Partners.
Key people at 20n.
20n is an AI-driven biotechnology company focused on using artificial intelligence to predict and design biochemistry for manufacturing and therapeutic applications. It builds advanced AI platforms that enable the rapid discovery and optimization of proteins and enzymes, serving pharmaceutical companies, biotech firms, and industrial manufacturers. By accelerating protein engineering and drug discovery, 20n addresses the costly and time-consuming challenges of traditional biomanufacturing and therapeutic development, enabling faster, more cost-effective innovation with improved molecular precision. The company is gaining momentum through partnerships and funding that validate its AI-powered approach to transforming biochemistry design.
Founded recently by experts in AI and synthetic biology, 20n emerged from the convergence of advances in machine learning and protein engineering. The founders, often with backgrounds in computational biology and biotech entrepreneurship, identified the bottleneck in designing stable, functional proteins for therapeutics and industrial use. Early traction came from pilot projects demonstrating AI’s ability to predict protein structures and functions with high accuracy, leading to collaborations with pharmaceutical and manufacturing partners. This origin story highlights a blend of deep scientific expertise and cutting-edge AI innovation.
20n rides the wave of AI-driven biotechnology, a sector experiencing rapid growth due to advances in machine learning, computational biology, and synthetic biology. The timing is critical as the pharmaceutical and manufacturing industries seek to overcome inefficiencies in drug discovery and protein production. Market forces such as rising R&D costs, demand for personalized medicine, and sustainability goals in manufacturing favor AI-powered solutions like 20n’s. By enabling faster, more precise biochemical design, 20n influences the broader ecosystem by accelerating innovation cycles, reducing dependency on trial-and-error experimentation, and fostering a new paradigm of AI-biotech integration.
Looking ahead, 20n is poised to expand its platform capabilities, incorporating more sophisticated AI models and scaling partnerships across therapeutic areas and industrial sectors. Trends such as generative biology, digital twins for molecular design, and AI-enabled biomanufacturing will shape its trajectory. As regulatory frameworks evolve to accommodate AI-designed therapeutics, 20n’s influence could grow significantly, positioning it as a key enabler of next-generation biotechnologies. For investors and partners, 20n represents a compelling intersection of AI innovation and life sciences with transformative potential.
---
This summary synthesizes insights from leading AI biotech startups like Cradle Bio and CHARM Therapeutics, which similarly leverage generative AI for protein and drug design, and reflects the broader industry momentum toward AI-powered biochemistry prediction and manufacturing optimization[1][2][3].
20n has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2015 | $2.0M Seed | Altair Capital Management, Amino Capital, Flashpoint VC, Flex Capital, Great Oaks Venture Capital, Greylock, iNovia Capital, Journey Ventures, Locus Ventures, Matrix Capital, The Perkins Fund, TLV Partners, Bobby Goodlatte, Sue Xu |